CA2767899A1 — Nitrogen-containing spiro-ring compound and medicinal use of same
Assigned to Japan Tobacco Inc · Expires 2011-02-03 · 15y expired
What this patent protects
Disclosed are a compound represented by general formula [I], a pharmaceutically acceptable salt thereof or a solvate of the same, and medicinal use thereof for treating rejection in organ transplantation, graft-versus-host reaction after organ transplantation, autoimmune diseases…
USPTO Abstract
Disclosed are a compound represented by general formula [I], a pharmaceutically acceptable salt thereof or a solvate of the same, and medicinal use thereof for treating rejection in organ transplantation, graft-versus-host reaction after organ transplantation, autoimmune diseases, allergic diseases and chronic myeloproliferative diseases by using these compounds as the active ingredient. In general formula [I], Ra's are the same or different and represent (1) a C1-6 alkyl group, etc.; n1 represents an integer of 0 to 4; Rb's are the same or different and represent (1) a C1-6 alkyl group, etc.; n2 represents an integer of 0 to 4; m1 represents an integer of 0 to 3; m2 represents an integer of 1 to 4; Xa=Xb represents (1) CH=CH, etc.; X represents (1) a nitrogen atom, etc.; and Rc represents (1) a hydrogen atom, etc.
Drugs covered by this patent
- Corectim (DELGOCITINIB) · Japan Tobacco
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.